The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence. Clin Cancer Res; 23(20); 5999–6001. ©2017 AACR.
See related article by Messenheimer et al., p. 6165
http://ift.tt/2hFodKP
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου